Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02174250 · ClinicalTrials.gov registry record · Phase 1
The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.
A Phase 1 study, sponsored by Kyowa Kirin Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02174250 is a Phase 1 study that has completed, run by Kyowa Kirin Co.. The registered enrollment target is 20 participants.
The verdict
NCT02174250, a Phase 1 study, has completed, sponsored by Kyowa Kirin Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to test whether Rifampin affects blood levels of istradefylline in humans. Rifampin could possibly decrease istradefylline levels.
Interventions
- DRUG Istradefylline 40 mg
- DRUG Rifampin 300mg BID + istradefylline 40mg Day 8 only
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-06 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02174250
The ClinicalTrials.gov registry entry for NCT02174250 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyowa Kirin Co., which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Istradefylline 40 mg is the first listed.
NCT02174250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02174250 about?
NCT02174250 is a clinical study titled "The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.". The purpose of this study is to test whether Rifampin affects blood levels of istradefylline in humans. Rifampin could possibly decrease istradefylline levels.
What is the current status of trial NCT02174250?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2014-06. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02174250?
The interventions under investigation include: Istradefylline 40 mg (DRUG), Rifampin 300mg BID + istradefylline 40mg Day 8 only (DRUG).
Who is sponsoring clinical trial NCT02174250?
This trial is sponsored by Kyowa Kirin Co., which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.